Equinix, Inc. Total Cost of Revenue decreased by 1.0% to $1.19B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.4%, from $1.08B to $1.19B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 6.7% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $865.12M | $885.65M | $910.44M | $915.88M | $930.26M | $934.67M | $970.20M | $1.01B | $1.06B | $1.07B | $1.09B | $1.09B | $1.08B | $1.10B | $1.20B | $1.08B | $1.08B | $1.14B | $1.20B | $1.19B |
| QoQ Change | — | +2.4% | +2.8% | +0.6% | +1.6% | +0.5% | +3.8% | +3.7% | +5.5% | +0.8% | +2.2% | -0.1% | -0.8% | +1.5% | +8.9% | -9.4% | +0.0% | +5.4% | +4.9% | -1.0% |
| YoY Change | — | — | — | — | +7.5% | +5.5% | +6.6% | +9.8% | +14.1% | +14.4% | +12.6% | +8.4% | +2.0% | +2.7% | +9.5% | -0.6% | +0.2% | +4.0% | +0.2% | +9.4% |